1. Home
  2. GYRE vs CBNK Comparison

GYRE vs CBNK Comparison

Compare GYRE & CBNK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$6.01

Market Cap

606.4M

Sector

Health Care

ML Signal

HOLD

CBNK

Capital Bancorp Inc.

HOLD

Current Price

$36.30

Market Cap

560.3M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
GYRE
CBNK
Founded
2002
1974
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
606.4M
560.3M
IPO Year
2004
2018

Fundamental Metrics

Financial Performance
Metric
GYRE
CBNK
Price
$6.01
$36.30
Analyst Decision
Strong Buy
Buy
Analyst Count
2
2
Target Price
$17.00
$35.50
AVG Volume (30 Days)
96.7K
55.8K
Earning Date
05-08-2026
04-27-2026
Dividend Yield
N/A
1.52%
EPS Growth
N/A
60.85
EPS
N/A
0.73
Revenue
$275,000.00
N/A
Revenue This Year
$19.88
$16.20
Revenue Next Year
N/A
$8.52
P/E Ratio
N/A
$48.81
Revenue Growth
N/A
N/A
52 Week Low
$5.44
$26.40
52 Week High
$9.42
$37.00

Technical Indicators

Market Signals
Indicator
GYRE
CBNK
Relative Strength Index (RSI) 41.79 62.81
Support Level $5.74 $27.55
Resistance Level $8.28 $36.71
Average True Range (ATR) 0.29 1.06
MACD -0.08 -0.05
Stochastic Oscillator 9.33 71.79

Price Performance

Historical Comparison
GYRE
CBNK

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

About CBNK Capital Bancorp Inc.

Capital Bancorp Inc is a bank holding company. The company through its holdings operates as a commercial-focused community bank that serves businesses, not-for-profit associations, and entrepreneurs throughout the region. The bank operates through four divisions including Commercial Banking, Capital Bank Home Loans, OpenSky, and Windsor Advantage. The company generates majority revenue from the Commercial bank sector. Commercial Banking division focuses on providing personalized service to commercial clients throughout the operations supplemented by lending outside primary market as well as engaging in government guaranteed lending on a national basis.

Share on Social Networks: